Citation

Koblan KS, Hopkins SC, Sarma K, Gallina N, Jin F, Levy-Cooperman N, Schoedel KA, Loebel A. Drug Alcohol Depend. 2016; 159: 26-34.

Affiliation

Sunovion Pharmaceuticals Inc., Marlborough, MA, USA.

Copyright

(Copyright © 2016, Elsevier Publishing)

DOI

10.1016/j.drugalcdep.2015.10.029

PMID

26794682

Abstract

AIMS: The aim of this study was to evaluate the abuse potential of dasotraline, a novel dopamine and norepinephrine reuptake inhibitor with slow absorption (tmax, 10-12h) and elimination (t1/2=47-77h) that is in development for the treatment of attention deficit hyperactivity disorder (ADHD).

METHODS: Recreational stimulant users (N=48) who had specific experience with cocaine, and who were able to distinguish methylphenidate (60mg) versus placebo in a qualification session, were randomized, in a 6-period, double-blind, crossover design, to receive single doses of dasotraline 8mg, 16mg, and 36mg, methylphenidate (MPH) 40mg and 80mg, and placebo. The primary endpoint was the Drug Liking Visual Analog Scale (VAS) score at the time of peak effect (Emax).

RESULTS: There were no significant differences between the 3 doses of dasotraline and placebo on the drug liking VAS at Emax, and on most secondary endpoints. Both doses of MPH had significantly higher VAS-drug liking scores at Emax relative to both placebo (P<0.001 for all comparisons) and dasotraline 8mg (P<0.001), 16mg (P<0.001) and 36mg (P<0.01). The increase in heart rate for MPH and dasotraline 36mg showed a time-course that closely matched subject-rated measures such as Any Effects VAS.

CONCLUSIONS: In this study, dasotraline was found to have low potential for abuse, which may be, in part, related to its established pharmacokinetics (PK) profile, which is characterized by slow absorption and gradual elimination.

Language: en